Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394016 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
NCT01394016: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01394016 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 225 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (275% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01394016, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.
Primary Outcome
The number of participants with clinically significant findings in the study were reported in this outcome measure.
Interventions
- DRUG Fulvestrant
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2009-12-07 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
What the finished NCT01394016 record still lists
NCT01394016 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (275% higher).
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT01394016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01394016 about?
NCT01394016 is a clinical study titled "A Phase 1 Study of LY2835219 In Participants With Advanced Cancer". The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.
What is the current status of trial NCT01394016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2009-12-07. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT01394016?
The interventions under investigation include: Fulvestrant (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT01394016?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01394016's enrollment target sits among peer trials
225 223rd of 2000 higher than 1,774 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI